https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Archives by category » Clinical Trial News
NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis. In this connection, NKMax America treated the first patient in the SNK01-MX03 clinical trial, which is a single center, dose-escalation study for […]

Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506

Chinese biotech company Bio-Thera Solutions has started dosing in a phase 1 clinical trial to study the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Janssen Biotech’s Simponi (golimumab). The early-stage clinical study is a randomized two-arm, parallel-group trial that will have nearly 182 healthy volunteers. Each of the patients will be subjected to […]

Continue reading …
PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial

PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]

Continue reading …
Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

Continue reading …
89bio begins phase 1b/2a NASH clinical trial of BIO89-100

BIO89-100 NASH clinical trial : US-based biopharma company 89Bio has initiated a proof of concept phase 1b/2a clinical trial for BIO89-100, its NASH drug in development, by screening the first patients. The proof of concept trial will evaluate the glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in patients with nonalcoholic steatohepatitis (NASH) or patients […]

Continue reading …
Astellas doses first patient in phase 3 VMS trial of fezolinetant

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per […]

Continue reading …
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Continue reading …
Cyxone achieves safety, tolerability goals in T20K MS clinical trial

T20K MS clinical trial : Swedish biotech company Cyxone said that a phase 1 clinical trial for its drug candidate T20K for multiple sclerosis (MS) has confirmed its safety and tolerability in humans. Cyxone said that there were no serious adverse events in the early-stage infusion study. As the next step in its development program, […]

Continue reading …
RESET clinical trial results : Rivipansel flops in phase 3 trial in SCD

RESET clinical trial results : US pharma giant Pfizer’s rivipansel failed to meet the primary and key secondary efficacy endpoints of a phase 3 trial called RESET in sickle cell disease (SCD). The aim of the RESET clinical trial was to assess the efficacy and safety of rivipansel in sickle cell disease patients, aged six […]

Continue reading …
Verdiperstat phase 3 MSA clinical trial : Biohaven enrolls first patient

Verdiperstat phase 3 MSA clinical trial : US biopharma company Biohaven Pharmaceutical has enrolled the first patient in a phase 3 clinical trial to assess the efficacy and safety of verdiperstat (formerly known as AZD3241) in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disorder. Licensed from AstraZeneca in September 2018, verdiperstat is an […]

Continue reading …
Page 1 of 7123Next ›Last »